Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib plus BR in previously treated CLL
NCT01569295Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2012
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of idelalisib in chronic lymphocytic leukemia (CLL), sponsored by Gilead Sciences. Started Jun 2012; status: completed.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01569295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01569295.